SCHEMBL4324243

SCHEMBL4324243

NC(=S)NN=Cc1ccc(N2CCN(Cc3ccc(F)cc3)CC2)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
PKM P14618 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
ALDH1A1 P00352 3/20 0.44
ALOX12 P18054 2/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
GAA P10253 2/20 0.41
POLB P06746 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4324239 1.00 MAPT (0.48) MAPTDRD2DRD4DRD3PKM
SCHEMBL4334865 0.90 MAPT (0.51) MAPTDRD2DRD4DRD3L3MBTL1
SCHEMBL4334867 0.90 MAPT (0.51) MAPTDRD2DRD4DRD3L3MBTL1
SCHEMBL4331128 0.90 DRD2 (0.48) MAPTDRD2DRD4DRD3L3MBTL1
SCHEMBL4331135 0.90 DRD2 (0.48) MAPTDRD2DRD4DRD3L3MBTL1
SCHEMBL4329372 0.88 THRB (0.45) MAPTL3MBTL1ALDH1A1ALOX12HPGD
SCHEMBL4329368 0.88 THRB (0.45) MAPTL3MBTL1ALDH1A1ALOX12HPGD
SCHEMBL4339014 0.87 MAPT (0.46) MAPTDRD2DRD4DRD3PKM
SCHEMBL4339011 0.87 MAPT (0.46) MAPTDRD2DRD4DRD3PKM
SCHEMBL4329338 0.87 ALDH1A1 (0.49) MAPTDRD2DRD4DRD3PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885DRD2 3561/4885DRD4 3597/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3876/4885DRD2 3440/4885DRD4 3150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.